Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression.

[1]  G. Marti,et al.  Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy , 2015, Clinical Cancer Research.

[2]  Brian Ruffell,et al.  Macrophages and therapeutic resistance in cancer. , 2015, Cancer cell.

[3]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[4]  J. Blay,et al.  Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. , 2014, Cancer cell.

[5]  J. Cayuela,et al.  Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. , 2014, Blood.

[6]  P. L. Bergsagel,et al.  TPL2 kinase regulates the inflammatory milieu of the myeloma niche. , 2014, Blood.

[7]  D. Rossi,et al.  Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia , 2014, Leukemia.

[8]  G. Juliusson,et al.  On the way towards a ‘CLL prognostic index’: focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort , 2014, Leukemia.

[9]  F. caligaris-Cappio,et al.  How the microenvironment wires the natural history of chronic lymphocytic leukemia. , 2014, Seminars in cancer biology.

[10]  J. Gribben,et al.  The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. , 2014, Seminars in cancer biology.

[11]  Jae-seok Roe,et al.  C/EBPα: critical at the origin of leukemic transformation , 2014, The Journal of experimental medicine.

[12]  C. Klein,et al.  Recombinant Human IL-15 Trans-Presentation by B Leukemic Cells from Chronic Lymphocytic Leukemia Induces Autologous NK Cell Proliferation Leading to Improved Anti-CD20 Immunotherapy , 2013, The Journal of Immunology.

[13]  Juthamas Sukbuntherng,et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[14]  L. Monti,et al.  Loss of function of Ribonuclease T2, an ancient and phylogenetically conserved RNase, plays a crucial role in ovarian tumorigenesis , 2013, Proceedings of the National Academy of Sciences.

[15]  A. Filip,et al.  Circulating microenvironment of CLL: are nurse-like cells related to tumor-associated macrophages? , 2013, Blood cells, molecules & diseases.

[16]  C. Lewis,et al.  Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.

[17]  M. Zucchetti,et al.  Role of macrophage targeting in the antitumor activity of trabectedin. , 2013, Cancer cell.

[18]  G. Fingerle-Rowson,et al.  Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor. , 2013, Blood.

[19]  A. Kohlmann,et al.  Protein Kinase C-β-Dependent Activation of NF-κB in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo , 2013, Cancer cell.

[20]  Zhi-ren Zhang,et al.  Macrophages in Tumor Microenvironments and the Progression of Tumors , 2012, Clinical & developmental immunology.

[21]  L. Pasqualucci,et al.  Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. , 2011, Blood.

[22]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[23]  L. Pasqualucci,et al.  Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation , 2011, The Journal of experimental medicine.

[24]  Jeffrey A Jones,et al.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. , 2011, Blood.

[25]  Richard Sherry,et al.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. , 2011, Blood.

[26]  A. Sica,et al.  Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase , 2010, Proceedings of the National Academy of Sciences.

[27]  D. Hume,et al.  An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. , 2010, Blood.

[28]  C. Klein,et al.  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.

[29]  G. Simonetti,et al.  A novel Rag2-/-gammac-/--xenograft model of human CLL. , 2010, Blood.

[30]  G. Kroemer,et al.  AIF: Not Just an Apoptosis‐Inducing Factor , 2009, Annals of the New York Academy of Sciences.

[31]  Hiroyuki Aburatani,et al.  The S100A8–serum amyloid A3–TLR4 paracrine cascade establishes a pre-metastatic phase , 2008, Nature Cell Biology.

[32]  P. Ghia,et al.  Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Rosenwald,et al.  High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. , 2007, Blood.

[34]  M. Keating,et al.  Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. , 2007, Blood.

[35]  Stefano Volinia,et al.  Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice. , 2006, Cancer research.

[36]  Silvano Sozzani,et al.  The chemokine system in diverse forms of macrophage activation and polarization. , 2004, Trends in immunology.

[37]  N. Van Rooijen,et al.  Subpopulations of Mouse Blood Monocytes Differ in Maturation Stage and Inflammatory Response1 , 2004, The Journal of Immunology.

[38]  Jiayou Zhang,et al.  Conditional macrophage ablation in transgenic mice expressing a Fas‐based suicide gene , 2004, Journal of leukocyte biology.

[39]  M. Fey,et al.  Disparate expression of the PTEN gene: a novel finding in B‐cell chronic lymphocytic leukaemia (B‐CLL) , 2003, British journal of haematology.

[40]  C. Croce,et al.  Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  T. Kipps,et al.  Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. , 2002, Blood.

[42]  H. Deeg,et al.  Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study , 2002, Leukemia.

[43]  N Tsukada,et al.  Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. , 2000, Blood.

[44]  N. Van Rooijen,et al.  Liposomes for specific depletion of macrophages from organs and tissues. , 2010, Methods in molecular biology.

[45]  H. Döhner,et al.  From pathogenesis to treatment of chronic lymphocytic leukaemia , 2010, Nature Reviews Cancer.

[46]  F. Batista,et al.  The who, how and where of antigen presentation to B cells , 2009, Nature Reviews Immunology.

[47]  W. Digel,et al.  Receptors for tumor necrosis factor on neoplastic B cells from chronic lymphocytic leukemia are expressed in vitro but not in vivo. , 1990, Blood.